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Type 1 diabetes (T1D) is a T cell-mediated disease. It is strongly associated with susceptibility haplotypes within the major
histocompatibility complex, but this association accounts for an estimated 50% of susceptibility. Other studies have identified as
many as 50 additional susceptibility loci, but the effect ofmost is verymodest (odds ratio (OR)<1.5).What accounts for the “missing
heritability” is unknown and is often attributed to environmental factors. Here we review new data on the cognate ligand of MHC
molecules, the T cell receptor (TCR). In rats, we found that one allele of a TCR variable gene, V𝛽13A, is strongly associated with
T1D (OR >5) and that deletion of V𝛽13+ T cells prevents diabetes. A role for the TCR is also suspected in NOD mice, but TCR
regions have not been associated with human T1D. To investigate this disparity, we tested the hypothesis in silico that previous
studies of human T1D genetics were underpowered to detect MHC-contingent TCR susceptibility. We show that stratifying by
MHCmarkedly increases statistical power to detect potential TCR susceptibility alleles. We suggest that the TCR regions are viable
candidates for T1D susceptibility genes, could account for “missing heritability,” and could be targets for prevention.
1. Introduction
Type 1 diabetes (T1D) is a T cell-mediated autoimmune
disease that afflicts a million persons in the USA [1, 2]. It is a
polygenic disorder resulting from the interaction of multiple
gene variants [3] and environmental factors [4]. No approved
methods are currently available for its prevention or reversal
[5]. Most interventions targeted at curing human T1D have
focused on either “secondary” or “tertiary” prevention, that is,
treating individuals who either have the disease or are at risk
based on family history and autoantibody titers [5]. To date,
no intervention has achieved the degree of success required
for clinical adaptation [6].
New strategies for primary prevention in susceptible
individuals would be advantageous, attacking the problem
before it starts or at its earliest stages [7]. Primary prevention,
however, requires accurate predictive genetic tools. Treat-
ment of individuals who would have remained diabetes-free
poses serious pragmatic and ethical issues.
The major genetic loci for diabetes susceptibility are
within the human leukocyte antigen (HLA) region, specifi-
cally those encoding HLA-DR and DQ antigens, with a less
significant independent contribution from HLA class I genes
[8–10]. Several high-risk HLA class II haplotypes account for
∼40% of the predisposition to T1D, with an odds ratio of
∼6.8, but accounting for the remaining 60% is an unresolved
problem [3]. The insulin genes VNTR, PTPN22, and CD25
are associated with odds ratios >1.5, and rare alleles of IFIH1
have an odds ratio (OR) near 0.5 [11]. More than 40 non-
MHC genes/regions, most involved in immune responses,
have statistically significant associations, but with OR <1.5
[11, 12].
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Unfortunately, although low-resolution HLA-genotyping
will identify most individuals at risk for T1D, only 1/15 or
∼7% of individuals with one of the highest risk HLA geno-
types (known as “DR3/DR4”) will actually become diabetic
[13]. Additional genetic knowledge has not yet significantly
improved prediction. An early estimate of sibling relative
risk (𝜆s) for T1D was estimated to be quite high at 15 [14].
Predictions of T1D, incorporating bothHLA and all currently
known loci, generate a 𝜆s of only 5 [3, 15], although a recently
reported strategy based on combining multiple risk alleles
appears to hold promise [16].
2. The TCR and ‘‘Missing Heritability’’
A possible explanation for our inability to predict T1D
accurately based on genotyping is the effect of environmental
perturbants [21]. There is clear seasonal and geographic
variation in the onset of T1D [22], and miniepidemics of
the disease have been documented [23]. Viral infection is
thought to be the most likely perturbant, and it remains
a topic of intense investigation [24]. Although there is no
good evidence for direct infection of pancreatic beta cells, the
immune response to infection might easily provoke disease
onset in genetically predisposed individuals. Most of the
genes and loci identified by genome-wide association study
(GWAS) analyses of T1D are involved in immune responses
[11], and the interaction of random infection with such genes
(“environmental genetics”) is a plausible way to account for
the “missing heritability.”
We would like to suggest, however, that there may be an
overlooked genetic element that has not been detected for
technical reasons, specifically the genome-encoded parts of
the T cell receptor (TCR). The TCR is the cognate partner of
major histocompatibility complex (MHC) molecules in the
peptide-MHC (pMHC) unit (Figure 1), and T1D is clearly
a T cell-mediated disease. Nonetheless, there is very little
evidence that germline TCR haplotype is important in sus-
ceptibility to T1D. There are, however, linkages to TCR in
human autoimmune diseases other than T1D. TCR genotype
has been implicated in multiple sclerosis (MS) [25]. There
are also well-documented associations of TCR genotype with
other forms of autoimmunity including Sjogren’s syndrome
[26, 27] and narcolepsy [28–30], which has a TCRA bias.
Of course, because approximately 1015 V-(D)-J recom-
bined TCRs are possible, it is not surprising that a role
for germline-encoded TCR usage, with far less diversity
than the recombined genes, has met with skepticism. New
data, however, suggest that the genome-encoded TCR is
likely to play a critical, previously unrecognized role in the
pathogenesis of T1D. Here we review our data that point to a
role for genome-encoded TCR susceptibility to T1D and then
present new quantitative analyses that attempt to account for
the failure of previous studies to detect such an effect.
3. Evidence from the Rat
3.1. Gene Mapping. Type 1-like autoimmune diabetes, both
spontaneous and inducible, is relatively common among
MHC
TCR𝛽
Peptide
TCR𝛼
Figure 1:The trimolecular TCR-pMHC complex that is fundamen-
tal in T1D susceptibility.
Table 1: Type 1 diabetes frequency in rats as a function of MHC and
TCR genotypes.
TCR MHC Diabetes Strains
V𝛽13a present RT1B/Du
High
susceptibility to
diabetes
BBDP and BBDR
LEW.1WR1 and
LEW.1AR1-iddm
KDP
PVG.RT1u
V𝛽13a absent RT1B/Du Low penetranceof T1D WF
V𝛽13a present Non-RT1B/Du No T1D Many
Coassociation of Class II MHC haplotype and TCR usage in T1D in rats [17–
19].
inbred rat strains that, like humans, express a high-risk class
II MHC haplotype. In rats, this is designated RT1B/Du [19, 31,
32]. We have previously reported that Iddm14 (formerly des-
ignated Iddm4) is a dominant non-MHC susceptibility locus
important for both spontaneous and induced autoimmune
diabetes in multiple rat strains [18, 33–38].
Studies of Iddm14 in eight RT1B/Du rat strains led to the
identification of a susceptibility haplotype in the Tcrb-V locus
[18]. Sequencing and single nucleotide polymorphism (SNP)
haplotype mapping revealed that 6 rat strains susceptible to
diabetes (KDP, BBDR, BBDP, LEW.1WR1, LEW.1AR1-iddm,
and PVG-RT1u) all share one allele of the beta chain variable
region gene Tcrb-V13 (designated Tcrb-V13S1A1) [20]. Three
rat strains that are resistant to, or confer resistance to, diabetes
in genetic studies, all express different alleles, either Tcrb-
V13S1A2 in the case of BN and WF rats, or Tcrb-V13S1A3P
in the F344 rat [20]. These polymorphisms are of interest
because the Tcrb-V13S1A1 gene product, designated V𝛽13a,
is used more by CD4+ than CD8+ cells [20]. Taken in the
context of additional data available from studies of rat T1D,
our findings suggest that it is the combination of MHC and
TCR that in largemeasure determines susceptibility to T1D in
the rat. As summarized in Table 1, only those rats that express
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bothRT1B/Du andV𝛽13a are highly susceptible toT1D. In the
absence of V𝛽13a, rats with a high-risk MHC are relatively
resistant to T1D, and in the absence of RT1B/Du essentially
no rats develop autoimmune diabetes.
These genetic observations, consistent with a critical role
for germline TCR usage in T1D in the rat, led us to hypoth-
esize that allele-specific TCR targeting could substantially
prevent disease. This hypothesis was confirmed in multiple
model systems, described below.
3.2. Depletion of V𝛽13+ T Cells Prevents Poly I:C-Triggered
T1D. LEW.1WR1 rats have a normal immunophenotype and
develop T1D spontaneously at a rate of 2.5% and after
treatment with polyinosinic: polycytidylic acid (poly I:C, a
TLR3 and IFIH1 ligand) at a rate of 90–100% [39]. After
documenting that anti-V𝛽13 monoclonal antibody (mAb)
reduces the number of V𝛽13+ T cells in vivo by about
60%, we compared diabetes frequency in rats treated with
either anti-V𝛽13 mAb or control mouse anti-human OKT8.
A second trial compared diabetes frequency in rats treated
with anti-V𝛽13 mAb, depleting anti-V𝛽16 mAb, or vehicle.
Diabetes frequency in rats treated with poly I:C and anti-
V𝛽13 mAb was 10% (2/20). In contrast, diabetes frequency
in controls averaged 85% (34/40, 𝑃 < 0.001) [17]. Histologic
study showed significantly less insulitis and nearly complete
preservation of beta cell insulin in animals treated with
depleting anti-V𝛽13 [17].
3.3. Depletion of V𝛽13+ T Cells Prevents Virus-Triggered T1D.
We also tested a model of triggered diabetes induced by
viral infection. Rats were given a small priming dose of poly
I:C followed by infection with Kilham rat virus (KRV). The
priming dose of poly I:C is by itself nondiabetogenic but
increases the penetrance of virus-triggered diabetes from
∼40% to∼100% [40].Diabetes frequency in anti-V𝛽13-treated
rats was 30% (3/10) as compared with 80% (8/10, 𝑃 = 0.03) in
both anti-V𝛽16 mAb treated animals and untreated controls.
3.4. Depletion of V𝛽13+ T Cells Prevents Spontaneous T1D.
BBDP rats develop spontaneous T1D at a rate of 60–90%
[31]. We treated cohorts of BBDP rats with vehicle, anti-
V𝛽13 mAb, or anti-V𝛽16 mAb. Treatment with anti-V𝛽13
mAb through 100 days of age completely prevented diabetes,
whereas diabetes occurred in vehicle injected and anti-V𝛽16
mAb treated rats at rates of 40% and 70%, respectively
(𝑃 < 0.01). Among rats still nondiabetic at the end of the
experiment, there was substantial “simmering” insulitis in
rats treated with anti-V𝛽16 mAb or vehicle [40].
These prevention studies were supplemented by addi-
tional immunological data showing a critical role for V𝛽13+
T cells early in T1D pathogenesis.
3.5. CD4+V𝛽13+ T Cells Are Abundant in Islets Early in the
Disease Process. The animal models of “triggered” T1D that
we use have well-defined kinetics and relatively rapid onset.
This allows us to harvest islets from animals very early during
disease onset and study the infiltrating inflammatory cells. By
day 5 CD4+V𝛽13+ T cells are remarkably abundant in the
prediabetic islet [40], reaching a peak on day 10, when overt
diabetes is first detectable.
3.6. V𝛽13/J𝛽 mRNA Transcripts in Prediabetic Islets Are
Skewed. Upon cloning the V𝛽13+ transcripts from early
prediabetic islets, we observed significant skewing of the
TCR𝛽 repertoire, with pauciclonal expansion of V𝛽13-CDR3
sequences from islet T-cells compared to a high diversity of
V𝛽13-CDR3s in spleen. These data suggested that antigen-
specific expansion of V𝛽13+ T cells occurs in the islets of
prediabetic rats. We also observed skewed TCR-J𝛽 usage in
islet-infiltrating V𝛽13+ T cells, with overrepresentation of
J𝛽1.3 and underrepresentation of J𝛽2.1 relative to peripheral
T cells. Spleen V𝛽13+ T cells from poly I:C treated and
untreated rats display skewing of individual J𝛽 segments.
In addition, the representation of different J𝛽 segments in
V𝛽16+ T cell transcripts was not skewed in the islets or
in the periphery. These results strongly support a role for
V𝛽13+ T cells in the early recognition of antigen in islets. In
addition, we showed that the TCR-V𝛼5 repertoire is skewed
among islet homing, sorted V𝛽13+ T cells. This is exciting
because TCR-V𝛼5D-4 is frequently used in the mouse T-cell
response to islet antigen and recognizes insulin B:9-23 [41,
42]. Collectively, these data indicate that an oligoclonal V𝛽13
response to pancreatic beta cells exists early in progression to
autoimmune diabetes.
4. Evidence from the NOD Mouse
In the NOD mouse, Abiru et al. have observed a dra-
matic TCR 𝛼 chain restriction (predominantly V𝛼5) in the
recognition of insulin autoantigen [44]. Retrogenic NOD
strains expressing V𝛼5D-4 𝛼 chains with many different
CDR3 sequences show that even those derived from TCRs
recognizing islet-irrelevant molecules develop anti-insulin
autoimmunity [41]. The germline encoded V𝛼5D-4 T cell
receptor targets a primary insulin peptide in NODmice [41].
In addition, induction of insulin autoantibody production by
helper T cells bearing V𝛼5D-4 𝛼 chains can be abrogated by
the mutation of two amino acid residues in CDR1 and CDR2
sequences of TRAV5D-4. TRAV13-1, the human ortholog of
murine TRAV5D-4, was also capable of inducing in vivo anti-
insulin autoimmunity in the NODmouse [41].
Nevertheless, the V𝛼 locus has never been detected
in mouse linkage studies to discover T1D genes. TCR-
V𝛼5D-4 is polymorphic in mice, with 5 identified alleles
differing by only 2–4 amino acids, but it also belongs to
a family of paralogous genes with >92% homology (Inter-
national ImMunoGeneTics information system or IMGT,
http://www.imgt.org/). There is a paralog in B6 that has
the same CDR1 and CDR2 as the important NOD paralog,
𝑉𝐴5𝐷4
∗
04. There are two non-CDR amino acid differences
in this B6 paralog, which by their position are unlikely to
contribute to the trimolecular complex [45]. This means
that both NOD and B6 strains could transmit an effective
diabetogenic allele of a TCR-V𝛼5D-4, and thus there would
be no apparent linkage to the V𝛼 locus (resulting in the Idd
designation) in a backcross or F2 [46].
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Figure 2: Nonsynonymous amino acid sequence alignments of beta chain CDR1 and CDR2 regions of V𝛽13a, found in T1D susceptible
(T1D-S) rats, and V𝛽13b, which is found in T1D resistant (T1D-R) rats [17, 20]. Both the CDR1 and CDR2 regions (red) exhibit differences
(all indicated in yellow). V𝛽13a is encoded by Tcrb-V13S1A1 and has been found in the BBDR, BBDP, LEW.1WR1, LEW.1AR1-iddm, KDP, and
PVGRT1u strains, all of which are T1D susceptible; V𝛽13b is encoded by Tcrb-V13S1A2 and is found in T1D resistant WF and BN rats [17].
Another allele, Tcrb-V13S1A3P, is a pseudogene found in the resistant F344 rat [17, 20].
A separate issue is whether a V𝛼 (and TCR-V𝛼5D-4 in
particular) selectively recognizes a permissive diabetogenic
MHC molecule. A hint that this might occur is found in the
mouse, where paralogs/alleles of TCR-V𝛼5D-4 likely influ-
ence differential selection on polymorphic MHC haplotypes.
This is supported by the finding that the expressed repertoire
of TCR-V𝛼5 paralogs in mice has a different frequency
distribution in the periphery of mice with different MHC-
II haplotypes [47]. In contrast, Iddm14 (TCR-V𝛽13-A1) was
discovered in rats in a linkage study because this TCR allelic
polymorphism exists among multiple strains bearing the
same high-risk MHC-II haplotypes.
5. Data That Point toward a Mechanism
Explaining the Role of TCR Genotype
5.1. Sequence Data in the Rat. The gene products of Tcrb-
V13S1A1 and Tcrb-V13S1A2 encode different amino acid
sequences for both the CDR1 and CDR2 regions of the
beta chain [20]. This polymorphism distinguishes WF and
other T1D-resistant strains from BBDR, BBDP, KDP, and
LEW.1WR1 T1D-susceptible strains, all of which share the
same class II MHC [18]. CDR1 and CDR2 sequences are
encoded within each Tcrb-V allele and are not altered by the
combinatorial processes that create the CDR3 regions of the
TCR (Figure 2).
The V𝛽13 sequences shown in Figure 2, which differen-
tiate our susceptible and resistant alleles of Tcrb-V13, differ
in both CDR1 and CDR2 and are consistent with emerging
data on structural elements of the TCR-pMHC synapse that
affect not only peptide recognition, but also binding affinity
and peptide registration [48].
5.2. Structural Analyses. Crystal structures of the TCR-
pMHC reveal the importance of the CDR1 and CDR2 regions
in the human immunological synapse (recently reviewed in
[48]). It is well accepted that CDR1 and CDR2 are critical
for T cell-MHC restriction [49], and new data reveal how
they interact with MHC helices to produce unanticipated
and potentially important effects. In one study of the TCR
“energetic landscape” it was noted that CDR1 and CDR2
loops act in a major way to stabilize the ligated CDR3 loops
[50].
Another recent crystallographic study was designed
specifically to address the question of whether shared
germline contacts within the TCR-pMHC would persist
despite distinct CDR3-peptide contacts in the model system,
and they do [51]. The authors concluded that, “. . .a TCR
utilizing entirely distinct chemistries to recognize different
peptides exhibits highly persistent germline-mediated con-
tacts.”
Studies by Sethi et al. have reported the crystal structure
of a TCR from a patient with multiple sclerosis that engages
its pMHC ligand in an unusual manner [52]. The TCR is
bound in a highly tilted orientation that prevents interaction
of the TCR-𝛼 chain with the MHC class II 𝛽 chain helix. In
this structure, only a single germline-encoded (i.e., CDR1 or
CDR2) TCRV𝛽 loop engages theMHCprotein. Furthermore,
the reduced interaction surfacewith the peptidemay facilitate
TCR cross-reactivity.
Finally, a very recent study shows biased TCR usage
against HLADQ8-restricted gliadin peptides in persons with
celiac disease [53]. These new data show that TCR usage
biased to 𝑇𝑅𝐵𝑉9∗01 underpins the recognition of HLA-
DQ8-𝛼-1-gliadin. More importantly for our hypothesis, they
show that “all CDR𝛽 loops (not just CDR𝛽3) interact with
the gliadin peptide.” They proved that “. . .Leu37𝛽 from the
CDR1𝛽 loop, and Tyr57𝛽 from the CDR2𝛽 loop are the
“hot spot” residues underpinning the SP3.4 TCR-DQ8-glia-
𝛼1 interaction providing a basis for the 𝑇𝑅𝐵𝑉9∗01 bias.”This
is precisely what our rat data predict to be true in T1D (which
is often comorbid with celiac disease). Interestingly, rat V𝛽13
is polymorphic in the analogous CDR1𝛽 position 37 “hot
spot” described for celiac disease, strengthening the notion
that allelic polymorphism in V𝛽13 may influence pMHC
interaction.
6. TCR Allelism in the Human Genome
A number of factors could affect investigations of the role of
genome-encoded TCR sequences in human T1D. One is the
issue of paralogs, which we discuss using the NOD V𝛼5D-
4 as an example. Like the NOD, humans could also have
multiple paralogs that are capable of binding insulin, and
thus, some linkage studies would not find a T1D gene in the
V𝛼 region if the parents each had one or more suitable V𝛼
paralogs. However, GWAS evaluates many more individuals
than a linkage study does, and would have more power
to detect those individuals who do not possess a suitable
allele of a V𝛼 chain paralog that detects insulin autoantigen.
Deep sequencing has not been performed on the V𝛼 and
V𝛽 regions in large numbers of people, so it is premature
to suggest that such individuals do not exist. To date,
however, the human TCR𝛼 locus does seem significantly less
complex than in rodents due to rat- and mouse-specific gene
duplication events and/or human specific gene convergence
Journal of Diabetes Research 5
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Figure 3: Genomic TRBV11-2 DNA sequences from Caucasian samples in the 1000 genomes database (including HG00328 (and HG00361,
HG00320, HG00111, HG00310, HG00247, HG00256, HG00231, HG00127, HG00103, HG00117, HG0032, not shown)), five expressed sequences
from the dbEST (indicated with gi numbers), two alleles of TRBV11-2 from IMGT, and four of the sequences we obtained at Drexel (1231,
1201, 00275, 00040) were translated and compared. Only TRBV11-2∗02 shows any nonsynonymous change (D105N, underlined, yellow
highlight), and it is substantiated by one transcript (M33235). The D105N change (which is residue 98 using IMGT numbering) forms a
salt bridge with a positive residue (Arg75) in the V𝛽 domain but is away from the pMHC (see Supplementary Figure 1 available online at
http://dx.doi.org//10.1155/2013/737485). Accordingly there could be some functional/structural consequence of that SNP, but given its location
(not in any CDR region) and conservative nature (Asp to Asn) it is unlikely that this is a functionally significant change.There is, however, no
proof that this is the case. Nucleotide substitutions reflecting known SNPs (rs183490568, rs149749379, rs148941368, rs139187012, rs76976752,
rs34112565, rs17163285, rs7777952, rs17281, rs17163283, rs17280, rs11505614, rs57147993, rs10375465, and rs17279) were commonly observed
among these sequences. Using these SNPs, four haplotypes (two homozygous and two heterozygous) were observed among the four Drexel
sequences.
(IMGT), so that human paralogsmight in fact not complicate
the genetic identification of a T1D gene in the V𝛼 region.
Another factor that could affect investigations of the
role of genome-encoded TCR sequences in human T1D
is the possibility of extensive undocumented allelism. To
investigate this possibility, we performed a preliminary study
and analyzed one TCR isotype, TRBV11-2, in detail as proof
of principle; it was selected because it is the human homolog
of rat Tcrb-V13. From the 1000 Genomes database [57],
we retrieved several TRBV11-2 sequences in which clear
null alleles were present (some with open reading frames
but no possibility of use in a TCR, as they did not have
proper predicted cysteines or tryptophans at key residues
([57], (http://www.imgt.org/)). Among the remaining 1000
Genomes Caucasian sequences were multiple examples bear-
ing the most common SNP variants, which supports the
expected average minor allele frequency (MAF) of several
of the SNPs in this region (0.21–0.43 among Caucasians,
1000 Genomes database). We sequenced a small number of
samples at Drexel, to determine the level of polymorphism in
this TCR element. The predominant TRBV11-2 allele among
our sequences is supported by numerous ESTs and cDNAs
(Figure 3). Interestingly, the UCSC database (hg19) [58] has
a reference sequence for TRBV11-2 with a stop codon in the
leader sequence, but all four of these TRBV11-2 genes have
an open reading frame throughout the entire gene. The low
read depth of sequencing, and the likely heterozygosity in
the 1000 Genomes database, can contribute to ambiguous
calls, leading us to question all but the most substantiated
alleles of 11-2. Therefore, we searched the NCBI EST/cDNA
databases for known transcripts with homology to TRBV11-2
(using BLAST), and these confirm the major alleles we found
by sequencing.Our results comparewith only two amino acid
substitution alleles recognized previously in IMGT.
To generate a comprehensive analysis of genomic TCR
effects in T1D, it will be necessary to collect alleles from each
chromosomeof heterozygous individuals.This information is
missing from any available database, as most report a single
sequence from each “person” in the cohort studied. As it is
likely that people are polymorphic for TCR V𝛽 regions, we
expect that many will be heterozygous.Thus, data are needed
to fill the gap in our knowledge about variation in TRAV
and TRBV as well as to contribute information on linkage
disequilibrium (LD) between the many different isotypes
within the TCR genomic complexes.
7. Molecular and Analytical Basis for
Identification of Human TCRs Involved
in T1D
7.1. Identifying and Mapping Known Human TCR Polymor-
phisms. To examine the possibility of germ-line human
TCR variants having a functional impact on the immune
repertoire and a potential impact on autoimmunity and T1D
in particular, we extended the analysis of polymorphism in
TRBV and compiled a comprehensive set of nonsynonymous
polymorphisms in the human TRAV and TRBV genes in
regions known to contact the pMHC (Table 2) [56]. In
addition to the CDR1 and CDR2 loops, we included the TCR
N-termini and HV4 loops, which often have 1-2 residues
contacting pMHC [59, 60]. Our results (Table 2) indicate that
there is a notable degree of polymorphism in both the TCR𝛼
and TCR𝛽 chains, in regions with direct impact on pMHC
binding. This was also noted in a previous study of human
TRAV gene diversity where the authors found that nucleotide
diversity was “substantially higher in the CDRs versus the
FRs (framework regions)” [56]. This diversity is observed in
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Table 2: Previously identified polymorphisms in TRAV/TRBV genes near the pMHC interface.
TCR Location1 Polymorphism(s)2 Genes2
N-term N2D TRAV9-2
CDR1𝛼 V27M, G29V, G29R, N30S, P30E, P30Q, N31D, Y32S TRAV36, TRAV12-2, TRAV8-4, TRAV14-1, TRAV38-1,TRAV20
CDR2𝛼 F55S, Q56E, A57G, V57M, S58T, T58I, A59G, K59E,Q61E
TRAV12-2, TRAV1-1, TRAV8-4, TRAV14-1, TRAV25,
TRAV8-7, TRAV26-2, TRAV38-1
CDR1𝛽 A30V, N30E TRBV7-7, TRBV6-6
CDR2𝛽 Q55H, Q57H, V57I, D58N, G60D, S60C, Q60H, L61I TRBV9, TRBV19, TRBV30, TRBV15, TRBV20-1,TRBV10-1, TRBV3-1
HV4𝛽 G84E TRBV7-2
1Region of the TCR variable domain tertiary structure. CDRs are as defined by Lefranc et al. [54], with CDR2 extended by one residue at the N-terminus to
account for pMHC contacts with this position. 2From IMGT [55], as well as additional data fromMackelprang et al. [56] (in bold italics). IMGT TCR residue
numbering used.
a total of 19 positions and 22 genes, including the TRBV9
gene, which, as noted above, is implicated in celiac disease
[53].
It is not certain whether the particular polymorphism
in TRBV9 (Q55H) plays a key role in recognition of the
gliadin-HLA-DQ8 celiac disease antigen (see above), though
a structural and biophysical study of the TK3 TCR, which
is encoded by the TRBV9 gene, found that this particular
variant affected the electrostatic makeup and structure of
pMHC recognition for HLA-B∗35:01 and an EBV peptide
[61].
To provide a structural context for these TCR sequence
polymorphisms, we mapped their positions onto the struc-
ture of a complex of a TCR with a Class II MHC and peptide
(Figure 4). While not all TCRs exhibit the same docking
geometry, this particular complex [62] has a typical pMHC
docking angle (49∘) and is, thus, approximately representative
of a variety of known complexes [63]. These polymorphisms
in germ-line encoded TCR genes have a clear potential to
impact the pMHC recognition, and, as the figure indicates,
primarily via interaction with MHC helices. Additionally,
a subset of these variants (including TCR𝛽 position 55
in the case of the TK3 TCR [61]) have the potential to
directly interact with the peptide as well. It is worth noting
that additional positions outside of those analyzed here
can potentially impact pMHC binding, given that TCRs
are known to exhibit long-range energetic effects [64, 65]
and long-range dynamic coupling between distal TCR sites
[66]. It should also be noted that Table 2 is very likely an
incomplete representation of TCR polymorphisms, and next
generation sequencing of T cells from diseased populations,
in conjunction with larger-scale studies of exome sequencing
(including the 1000 Genomes project [67]), should yield
valuable data on TCR polymorphisms and insights into their
impact on autoimmune diseases like T1D and control of
infection.
7.2. Improving Detection via Targeted Genotyping and Next
Generation Sequencing. The question remains, then: why
have such putative TCR alleles not been detected in GWAS
studies? To address this issue, we performed a quantitative
Figure 4: TRAV and TRBV polymorphic positions shown on a
TCR/pMHC complex structure. Polymorphic positions are red,
TCR𝛼 is light blue, TCR𝛽 is blue, peptide is magenta, and MHC
is green. Structure shown is HA1.7 TCR/HA peptide/HLA-DR4
(Protein Data Bank [43] ID 1J8H). The figure was generated using
PyMOL (http://www.pymol.org/).
analysis. Assume that some TCRV allele, call it “Vx,” is
important for T1D in individuals with a particular HLA-
DRB1 allele (e.g., HLA-DRB1∗03:01, which will be referred to
here as DR3). We base this assumption on our data showing
that V𝛽13a is important for T1D in MHC Class II RT1Bu rats.
Our remaining analysis is as follows.
7.2.1. Stratification by DR Allele. The ability to detect a
causative “Vx” TCR allele may be dramatically improved
by stratifying disease population by HLA-DR allele. Here
we consider stratification by HLA diplotype (rather than
presence of one haplotype alone), based on the impact
of trans-encoded HLA proteins on T1D susceptibility and
immune function [8, 68], as observed for the high-risk trans-
encoded HLA-DQA1∗05:01/DQB1∗03:02. Additionally, this
will control for the potential confounding effects of another
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Figure 5: Calculated improvement in odds ratio (OR) when
stratifying by HLA-DR-DQ genotype (ORDR) versus analyzing all
T1D patients (ORAll) for detection of a putative risk TCR allele.
Shown are data for homozygous HLA-DR3/3 and the high-risk
DR3/4-DQB1∗03:02 diplotype.
HLA allele whose interaction with a different TCR could
confer either additional susceptibility or resistance. However,
such analysis (and stratification) can be applied for single
alleles (i.e., the percentage of the T1D population with at
least one copy of an allele), though haplotype frequencies (as
given in Table 2 of Erlich et al. [8]) would not suffice. This is
because they provide overall frequency of haplotypes within
all diploid genomes (not distinguishing between homozygous
and heterozygous).
As an example, we will focus on one of the high-risk
HLA alleles, DR3, but the argument can be applied to any
allele of interest.The frequency ofDR3/3 homozygotes inT1D
patients is 7.6% [8]. Assuming that the “Vx” allele is relevant
in the context of HLA-DR3/3 and not the remainder of the
HLA-DR allele combinations, the odds ratio seen for all T1D
subjects (ORAll) is scaled accordingly from the odds ratio
of “Vx” within the DR3/3 T1D population (ORDR3/3) by the
DR3/3 frequency:
ORAll = 0.076 ∗ORDR3/3 + 0.924. (1)
A comparison of stratified versus unstratified ORs is
shown in Figure 5, for both DR3/3 and another diplo-
type (𝐻𝐿𝐴-𝐷𝑅3/4-𝐷𝑄𝐵1∗03:02), which is more frequent
in T1D (38% of the T1D population with European
ancestry [8]) and contains the high-risk trans-encoded
𝐻𝐿𝐴-𝐷𝑄𝐴∗05:01/𝐻𝐿𝐴-𝐷𝑄𝐵∗03:02 noted above. Even for
a relatively modest value of ORAll (1.1, which is below the
level of most identified genes in GWAS studies [11]), the OR
for DR3/3 becomes appreciably higher (2.3) and somewhat
higher (1.27) for 𝐷𝑅3/4-𝐷𝑄𝐵1∗03:02. Given these odds
ratios, for a study with 2000 patients, 2000 controls and back-
ground allele frequency of 10%, power to detect the risk TCR
allele increases from 16% to 75% for𝐷𝑅3/4-𝐷𝑄𝐵1∗03:02, and
to 100% for DR3/3 (G∗Power version 3.1, Fisher’s two-tailed
exact test, 𝛼 = 0.05).This implies that for previous studies that
did not include stratification by HLA alleles, detection of a
“Vx” allelemay have been confounded by dilution of the odds
ratio.
This analysis helps explain why a TCR 𝛼 chain locus
associated with autoimmune narcolepsy was identified using
GWAS [29]. That study was stratified by default because a
single HLA haplotype (𝐷𝑅𝐵1∗15:01-𝐷𝑄𝐵1∗06:02) is seen in
90% of cases [69]. That study did not identify the specific
allele of a TCR that confers narcolepsy, though one might be
identified using next generation sequencing (NGS).
7.2.2. NGS versus GWAS Array Coverage. Traditionally, anal-
ysis of polymorphisms in T1D has involved genome-wide
association studies (GWASs), which rely on arrays with
defined sets of probes, to infer the genotype in different
regions of the locus. An analysis of linkage disequilibrium
(LD) at the human TRAV locus found that it is highly
variable, leading the authors to conclude that, “even with
relatively dense coverage, it is unlikely that a genotyping
strategy (as opposed to a resequencing strategy) will provide
adequately dense coverage extending into the 𝑉 genes” [56].
We examined this contention further using a dataset of
TRAV and TRBV SNPs downloaded from the UCSC genome
browser [58] (dbSNP [70] build 130), selecting only SNPs
found within TRAV and TRBV exons from IMGT reference
sequences [55]. This resulted in a total of 322 SNPs (158 in
TRAV exons and 164 in TRBV exons).We used the SNAPweb
server [71] to calculate the degree of correlation (𝑟2) of these
SNPs with three arrays used in previous studies of GWAS in
T1D (Affymetrix GeneChip 500K, Illumina 550K Infinium
and Affymetrix SNP Array 6.0) [72] and found average 𝑟2
of approximately 0.3, and approximately 25% of SNPs with
𝑟
2 of 0.8 or higher. This coverage is somewhat lower than
observed for common genome-wide SNPs from European
ancestry for the Affymetrix GeneChip 500 (commensurate
with values for the less common SNPs with MAFs of 1–5%)
[73], but since these SNPs were not classified by frequency
it is not possible to conclude that TRAV/TRBV coverage is
lower than the rest of the genome, or determine the coverage
of SNPs above a certain frequency threshold. Regardless, in
light of the previous findings of variable LD at these loci noted
above, these data support the notion that average 𝑟2 forTRAV
and TRBV SNPs is markedly lower than 1. As correlation
is directly proportional to power of GWAS studies [74], it
follows that there is likely at least some reduction in power to
detect putative TCR alleles, reinforcing the strategy of NGS
to genotype TCR polymorphisms.
8. Conclusion
The striking observations that have recently been made
in the NOD mouse and in multiple strains of rats that
are used to model T1D strongly suggest that elements of
the TCR, encoded at the level of the genome and not
subject to V-(D)-J recombination, may play a critical role in
T1D susceptibility in an MHC-dependent fashion. Assuming
these animal model systems are reliable, the likelihood is
8 Journal of Diabetes Research
high that the germline TCR regions are also important for
susceptibility to human T1D. This is not a new idea, but
no supporting data have been reported to date. However,
our quantitative analyses show that cogent statistical flaws in
previous approaches could account for the negative findings.
If an HLA-dependent TCR susceptibility paradigm can be
identified for human T1D in the future, it could open the
path to newways of preventing the disease, either by targeting
specific alleles of the TCR with deletion approaches or by
using small molecules to interfere with the specific TCR-
pMHC synapses that lead to the disease.
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